{"status": "OK", "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved.", "response": {"docs": [{"word_count": "1491", "slideshow_credits": null, "multimedia": [{"type": "image", "subtype": "wide", "width": 190, "height": 126, "url": "images/2007/06/29/business/0630-biz-webCOMBOthumb.jpg", "legacy": {"wideheight": "126", "widewidth": "190", "wide": "images/2007/06/29/business/0630-biz-webCOMBOthumb.jpg"}}, {"type": "image", "subtype": "thumbnail", "width": 75, "height": 75, "url": "images/2007/06/29/business/30combo.75.jpg", "legacy": {"thumbnail": "images/2007/06/29/business/30combo.75.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}}], "news_desk": "Business", "pub_date": "2007-06-30T00:00:00Z", "source": "The New York Times", "web_url": "http://www.nytimes.com/2007/06/30/business/30combo.html", "blog": [], "_id": "548c02e479881004157bc516", "headline": {"print_headline": "Old Drugs In, New Ones Out", "main": "Old Drugs In, New Ones Out"}, "subsection_name": null, "abstract": null, "section_name": "Business Day", "byline": {"original": "By ANDREW POLLACK", "person": [{"rank": 1, "firstname": "Andrew", "lastname": "POLLACK", "role": "reported", "organization": ""}]}, "print_page": "1", "document_type": "article", "type_of_material": "News", "keywords": [{"rank": "1", "value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "N"}, {"rank": "2", "value": "Biotechnology", "name": "subject", "is_major": "N"}, {"rank": "3", "value": "Antibiotics", "name": "subject", "is_major": "N"}, {"rank": "4", "value": "Medicine and Health", "name": "subject", "is_major": "N"}, {"rank": "5", "value": "Tests and Testing", "name": "subject", "is_major": "N"}], "lead_paragraph": "Biotechnology companies are betting that pairing old drugs can be a better business than inventing new ones from scratch.", "snippet": "Biotechnology companies are betting that pairing old drugs can be a better business than inventing new ones from scratch."}, {"word_count": 1488, "slideshow_credits": null, "multimedia": [], "news_desk": "Business/Financial Desk", "pub_date": "2007-06-30T00:00:00Z", "source": "The New York Times", "web_url": "http://query.nytimes.com/gst/fullpage.html?res=9C07E4D8173EF933A05755C0A9619C8B63", "blog": [], "_id": "4fd27c4c8eb7c8105d842967", "headline": {"main": "Old Drugs In, New Ones Out"}, "subsection_name": null, "abstract": "Biotechnology companies are pairing old drugs to invent new ones rather than investing in new ones from scratch, which can take years and cost hundreds of millions of dollars, with no guarantee of success; Pozen is developing combination drugs in partnerships with GlaxoSmithKline and AstraZeneca; Orexigen Therapeutics recently went public based on prospects of two combination drugs it is developing to treat obesity; Celator Pharmaceuticals has raised more than $40 million from venture capitalists to combine old cancer drugs in new way; helping propel trend is growing supply of drugs that have lost patent protection, providing lode of material to test for new found potential; information technology also plays central role for CombinatoRx; company relies on latest robotic drug-screening technology and software to test several thousand pairs of medicines each day; chart; photo (L)", "section_name": "Technology; Health; Business", "byline": {"original": "By ANDREW POLLACK", "person": [{"rank": 1, "firstname": "Andrew", "lastname": "POLLACK", "role": "reported", "organization": ""}]}, "print_page": "1", "document_type": "article", "type_of_material": "News", "keywords": [{"value": "COMBINATORX", "name": "organizations"}, {"value": "GLAXOSMITHKLINE", "name": "organizations"}, {"value": "OREXIGEN THERAPEUTICS", "name": "organizations"}, {"value": "CELATOR PHARMACEUTICALS", "name": "organizations"}, {"value": "POZEN INC", "name": "organizations"}, {"value": "ASTRAZENECA", "name": "organizations"}, {"value": "DIET AND NUTRITION", "name": "subject"}, {"value": "WEIGHT", "name": "subject"}, {"value": "GENERIC AND BRAND NAME PRODUCTS", "name": "subject"}, {"value": "COMPUTER SOFTWARE", "name": "subject"}, {"value": "DRUGS (PHARMACEUTICALS)", "name": "subject"}, {"value": "CANCER", "name": "subject"}, {"value": "INDUSTRY PROFILES", "name": "subject"}, {"value": "MEDICINE AND HEALTH", "name": "subject"}, {"value": "TESTS AND TESTING", "name": "subject"}, {"value": "INVENTIONS AND PATENTS", "name": "subject"}, {"value": "ROBOTS", "name": "subject"}, {"value": "COMPUTERS AND THE INTERNET", "name": "subject"}], "lead_paragraph": "Can an antipsychotic drug from the 1950s be paired with a 1980s antibiotic to shrink 21st-century tumors? Might an anticlotting drug help a steroid relieve arthritis? How about a cholesterol treatment and a pain reliever teaming up to tame diabetes? Alexis Borisy, the pharmaceutical industry's master matchmaker, is betting they can. And if he is right, he may have found a cheap and quick way to develop a new cornucopia of medicines.", "snippet": "Can an antipsychotic drug from the 1950s be paired with a 1980s antibiotic to shrink 21st-century tumors? Might an anticlotting drug help a steroid relieve arthritis? How about a cholesterol treatment and a pain reliever teaming up to tame diabetes? ..."}], "meta": {"offset": 0, "hits": 2, "time": 33}}}